IBRANCE® is for the patient who are subjected to hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread to other parts of the body.

A hormone–receptor–positive (HR+) tumor is a tumor which consists of cells that express receptors for certain hormones. The term most commonly refers to estrogen receptor positive tumors (i.e. tumors that contain estrogen receptor positive cells), but can also include progesterone receptor positive tumors. Estrogen-receptor-positive tumors depend on the presence of estrogen for ongoing proliferation. (wikipedia.org)

Hormone receptor-positive (HR-positive or HR+) breast cancer is a type of breast cancer that feeds on the presence of estrogen and progesterone hormones in the body to grow.

This type of breast cancer can be targeted with hormonal treatments to slow down the growth of the cancer cells or reduce the risk of recurrence. (News-medical.net)

IBRANCE is for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)—breast cancer that has spread to other parts of the body—or HR+/HER2- MBC.

Hormone receptor positive includes both estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) subtypes.

-If your subtype is ER+ and/or PR+, you’re more likely to respond to hormone therapies, like an aromatase inhibitor or fulvestrant, that reduce the effects of hormones.

-If your subtype is HER2-, your cancer cells have less HER2 protein expression and, therefore, are less likely to respond to anti-HER2 therapies.

HR+, HER2- is the most common subtype of metastatic breast cancer, representing approximately 60% of all cases.

IBRANCE combination therapy was studied in 2 different clinical trials. Whether you’ve previously received hormonal therapy for your metastatic disease before or not, talk to your healthcare team to learn if IBRANCE is right for you. (IBRANCE®)

IBRANCE works to put the brakes on cell growth in both healthy and cancer cells. This helps slow the progression of cancer, but it can also cause side effects, some of which are serious. (IBRANCE®)

IBRANCE is a prescription medicine used in adults to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread to other parts of the body (metastatic) in combination with:

-an aromatase inhibitor as the first hormonal based therapy in postmenopausal women or in men, or
-fulvestrant with disease progression following hormonal therapy.

(IBRANCE®)

Low red blood cell counts and low platelet counts.

**Call your doctor right away if you develop any of these symptoms during treatment:

–dizziness
-shortness of breath
-weakness
-bleeding or bruising more easily
-nosebleeds
-infections
-tiredness
-nausea
-sore mouth
-abnormalities in liver blood tests
-diarrhea
-hair thinning or hair loss
-vomiting
-rash
-loss of appetite

(IBRANCE®)

-Serious side effects of IBRANCE include:

Low white blood cell counts (neutropenia). Low white blood cell counts are very common when taking IBRANCE and may cause serious infections that can lead to death. Your doctor should check your white blood cell counts before and during treatment.

If you develop low white blood cell counts during treatment with IBRANCE, your doctor may stop your treatment, decrease your dose, or may tell you to wait to begin your treatment cycle. Tell your doctor right away if you have signs and symptoms of low white blood cell counts or infections such as fever and chills.

Before you take IBRANCE, tell your doctor if you:

-have fever, chills, or any other signs or symptoms of infection.
-have liver or kidney problems.
-have any other medical conditions.
-are pregnant or plan to become pregnant; IBRANCE can harm your unborn baby.

**Females who are able to become pregnant should use effective birth control during treatment and for at least 3 weeks after the last dose of IBRANCE.

**Males with female partners who can become pregnant should use effective birth control during treatment with IBRANCE for at least 3 months after the last dose of IBRANCE.

-are breastfeeding or plan to breastfeed. It is not known if IBRANCE passes into your breast milk. Do not breastfeed during treatment with IBRANCE and for 3 weeks after the last dose. (IBRANCE®)